

\*Please provide your CV of 1-2 pages in length including details of the following items. This will be posted on the conference website.

- **Full Name:** **Hyun Ae Jung**
- **Current Position & Affiliation:** **Associate Professor**
- **Country:** **Republic of Korea**

---

• **Educational Background:**

- 28 FEB 2007 MD Kyungpook National University, School of Medicine, Daegu, Korea (Medicine)
- 29 FEB 2012 MMS Sungkyunkwan University, School of Medicine, Seoul, Korea (Internal Medicine)
- 31 AUG 2014 PhD Sungkyunkwan University, School of Medicine, Seoul, Korea (Internal Medicine)

• **Professional Experience:**

- 01 MAR 2015- 28 FEB 2018 Clinical assistant professor  
Department of Internal Medicine, Hallym University Medical Center,  
Hallym University College of Medicine, Dontan, Korea
- 01 MAR 2018- 28 FEB 2021 Clinical assistant professor,  
Division of Hematology-Oncology, Department of Medicine,  
Samsung Medical Center, Seoul, Korea
- 01 MAR 2022-28 FEB 2023 Clinical associate professor,  
Division of Hematology-Oncology, Department of Medicine,  
Samsung Medical Center, Seoul, Korea
- 01 MAR 2023-Current Associate professor  
Division of Hematology-Oncology, Department of Medicine,  
Samsung Medical Center, Seoul, Korea

• **Professional Organizations:**

- Korean Society of Medical Oncology (Member)  
Korean Cancer Association (Member)  
Korean Cancer Study Group (Member)  
American Society of Clinical Oncology (Member)  
European Society of Medical Oncology (Member)

• **Main Scientific Publications:**

Totality outcome of afatinib sequential treatment in patients with EGFR mutation-positive non-small-cell lung cancer in South Korea (TOAST): Korean Cancer Study Group (KCSG) LU-19-22  
Transl Lung Cancer Res . 2022 Jul;11(7):1369-1379

**Hyun Ae Jung**, Min Hee Hong, Hyun Woo Lee, Kyung Hee Lee, Il Hwan Kim, Young Joo Min, Hee Kyung Ahn, Byoung Yong Shim, Yoon Hee Choi, Yun-Gyoo Lee, Jeong A Kim, Joung Soon Jang, Seong-Hoon Shin, Keon Uk Park, Jin Hyoung Kang, Keunchil Park

Clinical, Pathologic, and Molecular Prognostic Factors in Patients with Early-Stage EGFR-Mutant NSCLC, Clin Cancer Res. 2022 Oct 3;28(19):4312-4321

**Hyun Ae Jung**, Jinyeong Lim, Yoon-La Choi, Se-Hoon Lee, Je-Gun Joung, Yeong Jeong Jeon, Jae Won Choi, Sumin Shin, Jong Ho Cho, Hong Kwan Kim, Yong Soo Choi, Jae Ill Zo, Young Mog Shim, Sehhoon Park, Jong-Mu Sun, Jin Seok Ahn, Myung-Ju Ahn, Joungho Han, Woong-Yang Park, Jhngook Kim, and Keunchil Park

Continuation of Pembrolizumab with Additional Chemotherapy after Progression with PD-1/PD-L1 Inhibitor Monotherapy in Patients with Advanced NSCLC: A Randomized, Placebo-Controlled Phase II Study, Clin Cancer Res. 2022 Jun 1;28(11):2321-2328

**Hyun Ae Jung**, Sehhoon Park, Yoon-La Choi, Se-Hoon Lee, Jin Seok Ahn, Myung-Ju Ahn, and Jong-Mu Sun

A Phase II Study of Nivolumab plus Gemcitabine in Patients with Recurrent or Metastatic Nasopharyngeal Carcinoma (KCSG HN17-11), Clin Cancer Res. 2022 Oct 3;28(19):4240-4247.

**Hyun Ae Jung**, Keon-Uk Park, Sanghee Cho, Jinyeong Lim<sup>4</sup>, Keun-Wook Lee, Min Hee Hong, Tak Yun, Ho Jung An, Woong-Yang Park, Sergio Pereira, Chan-Young Ock, and Bhumsuk Keam

Multimodal treatments and outcomes for anaplastic thyroid cancer before and after tyrosine kinase inhibitor therapy: a real-world experience, Eur J Endocrinol 2021

Jun Park, **Hyun Ae Jung (co-first author)**, Joon Ho Shim, Woong-Yang Park, Tae Hyuk Kim, Se-Hoon Lee, Sun Wook Kim, Myung-Ju Ahn, Keunchil Park and Jae Hoon Chung

Metabolic parameters on baseline 18F-FDG PET/CT are potential predictive biomarkers for immunotherapy in patients with head and neck squamous cell carcinoma

2022 SEP Frontiers in Medicine

Hye Ryeong Kwon, Junhun Cho, Sehhoon Park, Se-Hoon Lee, Myung-Ju Ahn, Joon Young Choi, Kyung-Han Lee, **Hyun Ae Jung (corresponding author)** and Seung Hwan Moon

A phase II study of palbociclib for recurrent or refractory advanced thymic epithelial tumors (KCSG LU17-21) J Thorac Oncol. 2022 Oct 25;S1556-0864(22)01858-5

**Hyun Ae Jung**, Miso Kim, Hae Su Kim, MD, Joo-Hang Kim, Yoon Hee Choi, Jinhyun Cho, Ji Hyun Park, Keon Uk Park, Bo Mi Ku, Sehhoon Park, Jong-Mu Sun, Se-Hoon Lee, Jin Seok Ahn, Keunchil Park, Myung-Ju Ahn

The Role of Brain Radiotherapy Before First-Line Afatinib Therapy, Compared to Gefitinib or Erlotinib, in Patients with EGFR-Mutant Non-Small Cell Lung Cancer

Cancer Res Treat. 2022 Dec 27. doi: 10.4143/crt.2022.1344

**Hyun Ae Jung**, Sehhoon Park, Se-Hoon Lee, Jin Seok Ahn, Myung-Ju Ahn, Jong-Mu Sun

Trends in survival rates of non-small-cell lung cancer in with the use of molecular testing and targeted therapy, 2010-2020

JAMA Netw Open. 2023 Mar 1;6(3):e232002

**Hyun Ae Jung** (corresponding author) Chi SA, Yu H, Choi YL, Park S, Sun JM, Lee SH, Ahn JS, Ahn MJ, Choi DH, Kim K, Park K.

Longitudinal Monitoring of Circulating Tumor DNA From Plasma in Patients With Curative Resected Stage I-III A EGFR Mutant-Non-Small Cell Lung Cancer

J Thorac Oncol. 2023 Jun 10;S1556-0864(23)00607

**Hyun-Ae Jung**, Bo Mi Ku, Yeon Jeong Kim, Sehhoon Park, Jong-Mu Sun, Se-Hoon Lee, Jin Seok Ahn, Jong Ho Cho, Hong Kwan Kim, Yong Soo Choi, Yoon-La Choi, Sun Hye Shin, Byeong-Ho Jeong, Sang-Won Um, Hojoong Kim, Kyunga Kim, Myung-Ju Ahn, Jhngook Kim